DJIA 16,204.97 -211.61 -1.29%
NASDAQ 4,363.14 0.00 0.00%
S&P 500 1,880.05 -35.40 -1.85%
market minute promo


company name or ticker
Company Photos
(Click to zoom)

$1.5B Ariad Is Smaller But Similar To Pharmacyclics Before The $20B Buyout

ARIAD (ARIA) Presents Favorable Long-Term Data on Iclusig - Analyst Blog

JMP Sees A 'Negative Market Tone' In Biotechnology

Cancer Stocks: 2 to Sell, 1 to Buy

Advaxis, Ariad Pharmaceuticals, and Exelixis Inc. are three cancer fight companies that could generate out-sized gains for investors. A deeper look, however, suggests that only one company is a compelling buy right now.

Cancer Stocks: 2 to Sell, 1 to Buy

Advaxis, Ariad Pharmaceuticals, and Exelixis Inc. are three cancer fight companies that could generate out-sized gains for investors. A deeper look, however, suggests that only one company is a compelling buy right now.

What's Happening At The ASCO Conference?

Michael Price Invests in 11 Companies in First Quarter

Stifel Talks 5 Biotech Stocks

ARIAD (ARIA) Q1 Loss Wider than Estimates; Iclusig Grows - Analyst Blog

ARIAD (ARIA) Q1 Loss Wider than Estimates; Iclusig Grows - Analyst Blog

ARIAD (ARIA) Q1 Loss a Penny Wider than Expected - Tale of the Tape